Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04732949 · ClinicalTrials.gov registry record · Phase 3
Study to Assess Efficacy and Safety of Inhaled Interferon-β Therapy for COVID-19
A Phase 3 study, sponsored by Synairgen Research.
- Completed
- Registry status
- Phase 3
- Development phase
- 623
- Enrollment target
NCT04732949 is a Phase 3 study that has completed, run by Synairgen Research. The registered enrollment target is 623 participants.
The verdict
NCT04732949, a Phase 3 study, has completed, sponsored by Synairgen Research.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 623 participants
- Enrollment target
Study Summary
The purpose of this Phase III study is to confirm that SNG001 can accelerate the recovery of hospitalised patients receiving oxygen with confirmed Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2). Safety and other efficacy endpoints will also be assessed.
Interventions
- DRUG Placebo
- DRUG SNG001
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 623 participants |
| Start Date | 2021-01-12 |
| Est. Completion | 2022-02-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04732949
The ClinicalTrials.gov registry entry for NCT04732949 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 623 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Synairgen Research, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04732949 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04732949 about?
NCT04732949 is a clinical study titled "Study to Assess Efficacy and Safety of Inhaled Interferon-β Therapy for COVID-19". The purpose of this Phase III study is to confirm that SNG001 can accelerate the recovery of hospitalised patients receiving oxygen with confirmed Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2). Safety and other efficacy endpoints will also be assessed.
What is the current status of trial NCT04732949?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 623 participants. The study started on 2021-01-12. Estimated completion is 2022-02-10.
What interventions are being tested in trial NCT04732949?
The interventions under investigation include: Placebo (DRUG), SNG001 (DRUG).
Who is sponsoring clinical trial NCT04732949?
This trial is sponsored by Synairgen Research, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.